Arrowhead Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Results of operationsAug 4 →InsidersNo open-market buys. 10 insiders sold $36.2M, 44 of 62 sales on a 10b5-1 plan.→HoldersBlackRock 10.5%Avoro Capital 8.0%FMR 5.7%→Financing →PeersClosest companies: VRDN, BBIO, ROIV→
From the filings
Figures
- Revenue
- $669.5Mlast 12 months
- Net income
- −$320.0Mlast 12 months
- Operating cash flow
- −$36.3Mlast 12 months
- Cash and equivalents
- $54.8Mat the last balance sheet
- Shares outstanding
- 141.1M shareson issue